How Much Does Farxiga (Dapagliflozin) Cost in Nebraska in 2026?

Nebraska Retail Pricing: What You Will Actually Pay

The average cash-pay price for brand-name Farxiga at Nebraska retail pharmacies sits at approximately $620 per month in 2026, matching AstraZeneca's national list price. That figure applies to a 30-day supply of the standard 10 mg once-daily tablet. Prices vary modestly between Omaha, Lincoln, and rural pharmacies, but the spread is narrow because SGLT2 inhibitors remain under patent protection with no FDA-approved generic alternative on the market yet [1].

This $620 figure ranks dapagliflozin among the more expensive chronic-disease medications Nebraskans fill each month. For context, the FDA approved Farxiga for type 2 diabetes in 2014, then expanded the label to include heart failure with reduced ejection fraction in 2020 and chronic kidney disease in 2021 [2]. Each new indication brought more patients into the prescribing pipeline without a corresponding drop in price. Patients filling at independent pharmacies in western Nebraska report similar pricing to chain pharmacies in the Omaha metro area, as wholesale acquisition costs are set nationally by AstraZeneca [1].

Cash-pay pricing tools such as GoodRx or RxSaver occasionally surface coupons that reduce the out-of-pocket figure to the $500 to $560 range, but availability changes weekly. The most reliable discount path remains the manufacturer savings card, discussed below [1].

Nebraska Medicaid Does Not Cover Farxiga

Nebraska Medicaid does not include Farxiga on its preferred drug list as of 2026. This is a significant gap. Patients enrolled in Heritage Health managed care plans (the state's Medicaid delivery system) will find dapagliflozin excluded from formulary coverage, and prior authorization requests for off-formulary SGLT2 inhibitors are rarely approved without documented failure on preferred alternatives [3].

The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as first-line add-on therapy for patients with type 2 diabetes who have established cardiovascular disease or chronic kidney disease [4]. Nebraska's Medicaid formulary has not yet aligned with that recommendation for dapagliflozin specifically, though empagliflozin (Jardiance) may appear on some Heritage Health plan formularies depending on the managed care organization.

Patients who rely on Nebraska Medicaid and need dapagliflozin for heart failure or CKD should ask their prescriber to submit a prior authorization citing the DAPA-HF or DAPA-CKD trial data [5][6]. Approval is not guaranteed, but the clinical evidence supporting cardiovascular and renal outcomes with dapagliflozin is strong. In DAPA-HF (N=4,744), dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% compared with placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) [5].

Commercial Insurance Coverage Across Nebraska

Most commercial insurers operating in Nebraska (Blue Cross Blue Shield of Nebraska, Medica, UnitedHealthcare, Aetna) cover Farxiga on a Tier 2 or Tier 3 formulary position. Copays before manufacturer assistance typically range from $30 to $75 per month depending on the plan's cost-sharing structure [1].

Step therapy requirements are common. Many plans require documented trial of metformin (and sometimes a sulfonylurea or DPP-4 inhibitor) before authorizing an SGLT2 inhibitor for type 2 diabetes. For heart failure and CKD indications, step therapy is less frequent because SGLT2 inhibitors carry a distinct evidence base in those populations. The 2022 AHA/ACC/HFSA Heart Failure Guideline gives dapagliflozin a Class I recommendation for patients with heart failure and reduced ejection fraction, regardless of diabetes status [7].

"SGLT2 inhibitors have moved from diabetes drugs to foundational heart failure therapy," noted Dr. Milton Packer in his 2021 commentary in the New England Journal of Medicine. "The evidence base now rivals that of ACE inhibitors in HFrEF" [8].

Employer-sponsored plans in Nebraska's larger metro areas (Omaha, Lincoln, Bellevue) tend to offer better SGLT2 inhibitor coverage than individual marketplace plans purchased through Healthcare.gov. If your plan places Farxiga on a specialty tier, the AstraZeneca savings card can reduce your copay to as low as $0 per month for eligible commercially insured patients [1].

The AstraZeneca Savings Card: How It Works in Nebraska

AstraZeneca offers a manufacturer copay savings card for Farxiga that covers up to $175 per monthly fill for commercially insured patients. The card is accepted at all major Nebraska chain pharmacies (CVS, Walgreens, Hy-Vee Pharmacy, Baker's Pharmacy) and most independent pharmacies [1].

Eligibility rules are straightforward. You must have commercial insurance (not Medicare, Medicaid, Tricare, or any other government-funded program). You must have a valid prescription for Farxiga. The card reduces your out-of-pocket cost to $0 for patients whose insurance copay falls at or below $175. For patients with higher cost-sharing, the card subtracts $175 from the copay, and you pay the remainder.

The annual benefit cap is $2,100 per calendar year ($175 times 12 fills). Most commercially insured Nebraskans with a standard Tier 2 or Tier 3 copay will pay nothing out of pocket for the entire year. Enrollment is available online through the AstraZeneca patient portal or by calling the number on the Farxiga prescribing information [1].

Patients who hit their insurance plan's deductible phase (common in January and February with high-deductible health plans) will face the full $620 list price temporarily. The savings card still applies during this phase, reducing the cost by $175, leaving roughly $445 out of pocket until the deductible is met.

Compounded Dapagliflozin Through Nebraska 503A Pharmacies

Nebraska permits licensed 503A compounding pharmacies to prepare dapagliflozin formulations for individual patients with valid prescriptions. This is legal under federal law (section 503A of the Federal Food, Drug, and Cosmetic Act) provided the pharmacy compounds in response to a patient-specific prescription, uses bulk pharmaceutical-grade dapagliflozin, and does not produce copies of commercially available drugs in regular manufacturing quantities [9].

A few critical distinctions apply. Section 503A compounding is patient-specific. The prescriber writes for compounded dapagliflozin, a 503A pharmacy fills it for that individual patient, and the product cannot be mass-produced or shipped across state lines to states that restrict compounding of commercially available drugs. Nebraska does not prohibit 503A compounding of SGLT2 inhibitors, so the pathway is available.

Pricing for compounded dapagliflozin varies by pharmacy but has been reported in the range of $30 to $90 per month at Nebraska-based compounding pharmacies, a fraction of the $620 brand-name cost. The trade-off: compounded products are not FDA-approved, do not carry the same regulatory oversight as manufactured tablets, and are not tested in the clinical trials that established dapagliflozin's efficacy and safety profile [9].

Patients considering this route should verify that the compounding pharmacy holds a valid Nebraska Board of Pharmacy license, uses USP-grade ingredients, and follows USP <795> compounding standards. The Nebraska Department of Health and Human Services maintains a searchable pharmacy license database.

Telehealth Prescribing of Farxiga in Nebraska

Nebraska allows telehealth prescribing of Farxiga. The state's telehealth practice standards, updated through LB 400 and subsequent legislation, permit licensed prescribers to establish a patient-provider relationship via audio-video consultation and prescribe non-controlled medications including SGLT2 inhibitors [10].

This matters for rural Nebraskans. Roughly 35% of the state's population lives in rural areas where endocrinology, cardiology, and nephrology specialists are scarce. A patient in Alliance or North Platte can receive a dapagliflozin prescription through a telehealth visit with an Omaha- or Lincoln-based provider, then fill it at a local pharmacy or through mail-order.

Telehealth platforms that operate in Nebraska (including HealthRX) can prescribe Farxiga after a clinical evaluation confirms an appropriate indication. The prescription is sent electronically to the patient's preferred pharmacy, and all standard insurance and savings card benefits apply. No in-person visit is required for initial prescribing under current Nebraska telemedicine law [10].

Clinical Value: Why Dapagliflozin Costs What It Does

The pricing of Farxiga reflects AstraZeneca's investment in a large clinical trial program that reshaped treatment guidelines across three disease states. Understanding this context helps patients and prescribers evaluate whether the cost is justified for a given clinical scenario.

DAPA-HF (2019) enrolled 4,744 patients with heart failure and ejection fraction of 40% or less across 20 countries. Dapagliflozin 10 mg daily reduced the primary composite endpoint (cardiovascular death, heart failure hospitalization, or urgent heart failure visit) by 26% versus placebo, with a number needed to treat of 21 over 18.2 months [5]. The benefit appeared within weeks and was consistent regardless of baseline diabetes status.

DAPA-CKD (2020) enrolled 4,304 patients with chronic kidney disease (eGFR 25 to 75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio 200 to 5,000). Dapagliflozin reduced the primary composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [6]. The trial was stopped early for overwhelming efficacy.

"The magnitude of kidney protection seen with dapagliflozin in DAPA-CKD is among the largest observed in any nephrology trial in two decades," said Dr. Hiddo Heerspink, the trial's principal investigator, in a 2020 New England Journal of Medicine publication [6].

DECLARE-TIMI 58 (2019) studied 17,160 patients with type 2 diabetes and either established cardiovascular disease or multiple risk factors. Dapagliflozin met its primary safety endpoint and reduced heart failure hospitalization by 27% (HR 0.73; 95% CI 0.61 to 0.88) [11]. The trial did not show a significant reduction in major adverse cardiovascular events (MACE) in the overall population, which is an honest limitation compared with empagliflozin's EMPA-REG OUTCOME results.

Comparing Farxiga to Other SGLT2 Inhibitors in Nebraska

Two other SGLT2 inhibitors compete with Farxiga in Nebraska: empagliflozin (Jardiance) and canagliflozin (Invokana). Pricing is similar across the class, with Jardiance listing at approximately $620 per month and Invokana at roughly $580 per month [1].

Formulary positioning differs by insurer. Some Nebraska Blue Cross plans prefer Jardiance over Farxiga, while UnitedHealthcare plans may cover both at similar tiers. The clinical profiles overlap substantially, but the trial populations and endpoints vary.

Empagliflozin demonstrated a 38% reduction in cardiovascular death in EMPA-REG OUTCOME (N=7,020), a result Farxiga did not replicate in DECLARE-TIMI 58 [12]. Dapagliflozin's CKD data from DAPA-CKD is arguably stronger, as it enrolled patients with and without diabetes and showed benefit across a broader eGFR range [6]. For heart failure, both DAPA-HF and EMPEROR-Reduced showed similar effect sizes, and current guidelines treat the two drugs as interchangeable for HFrEF [7].

The practical question for Nebraska patients: which drug does your insurance cover at the lowest copay? If both are available, discuss with your prescriber whether your primary indication (diabetes, heart failure, or CKD) aligns better with one drug's trial evidence.

Steps to Reduce Your Farxiga Cost in Nebraska

Start with your insurance formulary. Call the member services number on your insurance card and ask whether dapagliflozin (Farxiga) is covered, what tier it sits on, and whether prior authorization or step therapy is required. If your plan covers Farxiga, enroll in the AstraZeneca savings card to reduce or eliminate your copay [1].

If you are uninsured, the AstraZeneca patient assistance program (AZ&Me) provides free Farxiga to qualifying patients with household income at or below 400% of the federal poverty level. For a single-person household in 2026, that threshold is approximately $62,400 annually [1].

If you are on Nebraska Medicaid, ask your prescriber whether empagliflozin or another SGLT2 inhibitor is covered under your Heritage Health plan. If none are covered, request a prior authorization for dapagliflozin citing the DAPA-HF or DAPA-CKD data and the ADA Standards of Care recommendation [4][5][6].

If cost remains prohibitive, ask your prescriber about compounded dapagliflozin through a Nebraska-licensed 503A pharmacy. Confirm the pharmacy's licensure status through the Nebraska Board of Pharmacy before filling.